Intervention not reported
Quality of life ‐ physical composite SGRQ and SF36 · people with COPD
1 finding from 1 review
Intervention not reported
Quality of life ‐ emotional composite SGRQ and SF36 · people with COPD
1 finding from 1 review
Intervention not reported
Exercise capacity 6MWD · people with COPD
1 finding from 1 review
Response · adults with Major Depressive Disorder
Vortioxetine may leads to higher response compared with placebo (low certainty).
1 finding from 1 review
Remission · adults with Major Depressive Disorder
It is very uncertain whether vortioxetine changes remission compared with SNRIs (very low certainty).
1 finding from 1 review
Depressive symptoms · adults with Major Depressive Disorder
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · adults with Major Depressive Disorder
It is very uncertain whether vortioxetine changes drop‐out due to adverse events compared with SNRIs (very low certainty).
1 finding from 1 review
Drop out due to inefficacy Number of participants who dropped out due to inefficacy during the trial, as a proportion of the total number of randomised participants · adults with Major Depressive Disorder
It is very uncertain whether vortioxetine changes drop‐out due to inefficacy compared with SNRIs (very low certainty).
1 finding from 1 review
Tolerability · adults with Major Depressive Disorder
Vortioxetine may leads to lower tolerability compared with SNRIs (low certainty).
1 finding from 1 review
Total number of drop‐outs · adults with Major Depressive Disorder
Vortioxetine showed no clear difference in total number of drop‐outs compared with placebo (moderate certainty).
1 finding from 1 review
Remission · adults with Major Depressive Disorder
Vortioxetine may leads to higher remission compared with placebo (low certainty).
1 finding from 1 review
Depressive symptoms · adults with Major Depressive Disorder
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · adults with Major Depressive Disorder
Vortioxetine probably leads to higher drop‐out due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Drop out due to inefficacy Number of participants who dropped out due to inefficacy during the trial, as a proportion of the total number of randomised participants · adults with Major Depressive Disorder
Vortioxetine probably leads to lower drop‐out due to inefficacy compared with placebo (moderate certainty).
1 finding from 1 review
Tolerability · adults with Major Depressive Disorder
Vortioxetine probably leads to higher tolerability compared with placebo (moderate certainty).
1 finding from 1 review
Response · adults with Major Depressive Disorder
It is very uncertain whether vortioxetine changes response compared with SNRIs (very low certainty).
1 finding from 1 review
Total number of drop‐outs · adults with Major Depressive Disorder
It is very uncertain whether vortioxetine changes total number of drop‐outs compared with SNRIs (very low certainty).
1 finding from 1 review
Diagnosis of depression · Children or adolescents
Evidence‐based psychological interventions probably leads to lower evidence‐based psychological interventions versus any comparator… compared with any comparator (moderate certainty).
3 findings from 1 review
RR 0.84 [0.72, 0.97]
Studies not reported
Moderate
RR 0.82 [0.68, 0.99]
Studies not reported
Very low
RR 0.87 [0.66, 1.14]
Studies not reported
Moderate
Evidence‐based psychological interventions versus any comparator (Overall) ‐ self‐rated depression scores (higher score is equivalent to a poorer outcome) · Children or adolescents
1 finding from 1 review
Evidence‐based psychological interventions versus any comparator (Targeted ‐ self‐rated depression scores (higher score is equivalent to a poorer outcome)) · Children or adolescents
1 finding from 1 review